Definium shareholders approve 5M share increase in equity plan, re-elect directors

Definium Therapeutics, Inc.

Shareholders approved amendment to 2025 Equity Incentive Plan, increasing shares by 5,000,000 to 9,500,000 total.
All seven director nominees elected: Barrow, Bruhn, Crystal, Gryska, Krebs, Vallone, Adsett.
Appointment of KPMG LLP as independent auditor approved for fiscal year until 2027 annual meeting.
Quorum of 78,673,592 shares (approx. 72% of outstanding) was present at the June 11, 2026 meeting.
Equity Plan Amendment effective immediately upon shareholder approval at the Annual Meeting.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Definium Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-11 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

Proposal 1 – Election of Directors The Company’s seven nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone, and Roger Adsett, were each elected to serve as a member of the Board until the 2027 annual general meeting of shareholders (the “2027 Annual Meeting”) or until a successor has been duly elected or appointed, by the following votes: Company Board Nominee Votes For Votes Withheld Broker Non-Votes Robert Barrow 62,881,122 173,376 15,619,094 Dr. Suzanne Bruhn 62,503,873 550,625 15,619,094 Dr. Roger Crystal 60,056,178 2,998,320 15,619,094 David Gryska 62,760,423 294,075 15,619,094 Andreas Krebs 62,395,043 659,455 15,619,094 Carol A. Vallone 62,623,945 430,553 15,619,094 Roger Adsett 62,931,294 123,204 15,619,094

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Definium Therapeutics, Inc. shareholders approved Approval of the Equity Plan Amendment at the 2026-06-11 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

Proposal 3 – Approval of the Equity Plan Amendment The shareholders approved the Equity Plan Amendment by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 58,149,028 4,708,102 197,368 15,619,094

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Definium Therapeutics, Inc. shareholders approved Appointment of Auditor at the 2026-06-11 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

Proposal 2 – Appointment of Auditor The shareholders approved the appointment of KPMG LLP as the independent registered public accounting firm (auditor) of the Company until the 2027 Annual Meeting by the following votes: Votes For Votes Withheld Broker Non-Votes 78,579,054 94,538 -

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-269549

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.